Cargando…
OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review
BACKGROUND: With onabotulinumtoxinA approved for the treatment of glabellar and crow’s feet lines and, most recently, for forehead lines (FHL), it is possible to simultaneously treat multiple areas of the upper face that are of high concern and treatment priority for aesthetically oriented individua...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253259/ https://www.ncbi.nlm.nih.gov/pubmed/32537333 http://dx.doi.org/10.1097/GOX.0000000000002669 |
_version_ | 1783539308062310400 |
---|---|
author | De Boulle, Koenraad Carruthers, Alastair Solish, Nowell Carruthers, Jean Philipp-Dormston, Wolfgang G. Fagien, Steven Sangha, Sara Silberberg, Michael Mao, Cheri |
author_facet | De Boulle, Koenraad Carruthers, Alastair Solish, Nowell Carruthers, Jean Philipp-Dormston, Wolfgang G. Fagien, Steven Sangha, Sara Silberberg, Michael Mao, Cheri |
author_sort | De Boulle, Koenraad |
collection | PubMed |
description | BACKGROUND: With onabotulinumtoxinA approved for the treatment of glabellar and crow’s feet lines and, most recently, for forehead lines (FHL), it is possible to simultaneously treat multiple areas of the upper face that are of high concern and treatment priority for aesthetically oriented individuals. This review aims to present key insights on the use of onabotulinumtoxinA for the treatment of moderate to severe FHL. METHODS: Double-blind, placebo-controlled registration trials of onabotulinumtoxinA for the treatment of FHL were included. Using findings from 3 such published studies, we discuss key concepts and clinical experience for the treatment of moderate to severe FHL with onabotulinumtoxinA (20 U in the frontalis and 20 U in the glabellar complex, with/without 24 U in crow’s feet lines), including injection pattern, dose selection, efficacy and safety data, and considerations for patient selection. RESULTS: Across the 2 pivotal phase 3 studies, responder rates on investigator- and subject-assessed measures of appearance of FHL severity were significantly higher with onabotulinumtoxinA versus placebo for the treatment of FHL at day 30 (P < 0.0001), and results were maintained through 3 cycles of onabotulinumtoxinA. CONCLUSIONS: OnabotulinumtoxinA treatment also resulted in high patient satisfaction rates. The incidence of eyebrow and of eyelid ptosis was low, and no new safety signals were detected. OnabotulinumtoxinA is safe and effective and an appropriate option for patients with moderate to severe FHL encountered in clinical practice. |
format | Online Article Text |
id | pubmed-7253259 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-72532592020-06-11 OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review De Boulle, Koenraad Carruthers, Alastair Solish, Nowell Carruthers, Jean Philipp-Dormston, Wolfgang G. Fagien, Steven Sangha, Sara Silberberg, Michael Mao, Cheri Plast Reconstr Surg Glob Open Original Articles BACKGROUND: With onabotulinumtoxinA approved for the treatment of glabellar and crow’s feet lines and, most recently, for forehead lines (FHL), it is possible to simultaneously treat multiple areas of the upper face that are of high concern and treatment priority for aesthetically oriented individuals. This review aims to present key insights on the use of onabotulinumtoxinA for the treatment of moderate to severe FHL. METHODS: Double-blind, placebo-controlled registration trials of onabotulinumtoxinA for the treatment of FHL were included. Using findings from 3 such published studies, we discuss key concepts and clinical experience for the treatment of moderate to severe FHL with onabotulinumtoxinA (20 U in the frontalis and 20 U in the glabellar complex, with/without 24 U in crow’s feet lines), including injection pattern, dose selection, efficacy and safety data, and considerations for patient selection. RESULTS: Across the 2 pivotal phase 3 studies, responder rates on investigator- and subject-assessed measures of appearance of FHL severity were significantly higher with onabotulinumtoxinA versus placebo for the treatment of FHL at day 30 (P < 0.0001), and results were maintained through 3 cycles of onabotulinumtoxinA. CONCLUSIONS: OnabotulinumtoxinA treatment also resulted in high patient satisfaction rates. The incidence of eyebrow and of eyelid ptosis was low, and no new safety signals were detected. OnabotulinumtoxinA is safe and effective and an appropriate option for patients with moderate to severe FHL encountered in clinical practice. Wolters Kluwer Health 2020-03-18 /pmc/articles/PMC7253259/ /pubmed/32537333 http://dx.doi.org/10.1097/GOX.0000000000002669 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Articles De Boulle, Koenraad Carruthers, Alastair Solish, Nowell Carruthers, Jean Philipp-Dormston, Wolfgang G. Fagien, Steven Sangha, Sara Silberberg, Michael Mao, Cheri OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review |
title | OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review |
title_full | OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review |
title_fullStr | OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review |
title_full_unstemmed | OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review |
title_short | OnabotulinumtoxinA Treatment for Moderate to Severe Forehead Lines: A Review |
title_sort | onabotulinumtoxina treatment for moderate to severe forehead lines: a review |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253259/ https://www.ncbi.nlm.nih.gov/pubmed/32537333 http://dx.doi.org/10.1097/GOX.0000000000002669 |
work_keys_str_mv | AT deboullekoenraad onabotulinumtoxinatreatmentformoderatetosevereforeheadlinesareview AT carruthersalastair onabotulinumtoxinatreatmentformoderatetosevereforeheadlinesareview AT solishnowell onabotulinumtoxinatreatmentformoderatetosevereforeheadlinesareview AT carruthersjean onabotulinumtoxinatreatmentformoderatetosevereforeheadlinesareview AT philippdormstonwolfgangg onabotulinumtoxinatreatmentformoderatetosevereforeheadlinesareview AT fagiensteven onabotulinumtoxinatreatmentformoderatetosevereforeheadlinesareview AT sanghasara onabotulinumtoxinatreatmentformoderatetosevereforeheadlinesareview AT silberbergmichael onabotulinumtoxinatreatmentformoderatetosevereforeheadlinesareview AT maocheri onabotulinumtoxinatreatmentformoderatetosevereforeheadlinesareview |